KR20160136323A - 골수형성이상증후군 치료용 jak1 억제제 - Google Patents

골수형성이상증후군 치료용 jak1 억제제 Download PDF

Info

Publication number
KR20160136323A
KR20160136323A KR1020167026668A KR20167026668A KR20160136323A KR 20160136323 A KR20160136323 A KR 20160136323A KR 1020167026668 A KR1020167026668 A KR 1020167026668A KR 20167026668 A KR20167026668 A KR 20167026668A KR 20160136323 A KR20160136323 A KR 20160136323A
Authority
KR
South Korea
Prior art keywords
pyrimidin
pyrrolo
pyrazol
trifluoromethyl
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167026668A
Other languages
English (en)
Korean (ko)
Inventor
크리쉬나 바디
Original Assignee
인사이트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인사이트 코포레이션 filed Critical 인사이트 코포레이션
Publication of KR20160136323A publication Critical patent/KR20160136323A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y10S514/908—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167026668A 2014-02-28 2015-02-27 골수형성이상증후군 치료용 jak1 억제제 Ceased KR20160136323A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946124P 2014-02-28 2014-02-28
US61/946,124 2014-02-28
PCT/US2015/017963 WO2015131031A1 (en) 2014-02-28 2015-02-27 Jak1 inhibitors for the treatment of myelodysplastic syndromes

Publications (1)

Publication Number Publication Date
KR20160136323A true KR20160136323A (ko) 2016-11-29

Family

ID=52693052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167026668A Ceased KR20160136323A (ko) 2014-02-28 2015-02-27 골수형성이상증후군 치료용 jak1 억제제

Country Status (29)

Country Link
US (4) US20150246046A1 (cg-RX-API-DMAC7.html)
EP (1) EP3110409B1 (cg-RX-API-DMAC7.html)
JP (1) JP6576941B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160136323A (cg-RX-API-DMAC7.html)
CN (2) CN112494652A (cg-RX-API-DMAC7.html)
AU (1) AU2015222913B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940659C (cg-RX-API-DMAC7.html)
CL (1) CL2016002144A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160449A (cg-RX-API-DMAC7.html)
CY (1) CY1120857T1 (cg-RX-API-DMAC7.html)
DK (1) DK3110409T3 (cg-RX-API-DMAC7.html)
EA (1) EA201691745A1 (cg-RX-API-DMAC7.html)
ES (1) ES2688553T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181661T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041456T2 (cg-RX-API-DMAC7.html)
IL (1) IL247475B (cg-RX-API-DMAC7.html)
LT (1) LT3110409T (cg-RX-API-DMAC7.html)
MX (1) MX372939B (cg-RX-API-DMAC7.html)
MY (1) MY185392A (cg-RX-API-DMAC7.html)
PE (1) PE20161388A1 (cg-RX-API-DMAC7.html)
PL (1) PL3110409T3 (cg-RX-API-DMAC7.html)
PT (1) PT3110409T (cg-RX-API-DMAC7.html)
RS (1) RS57723B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201607083VA (cg-RX-API-DMAC7.html)
SI (1) SI3110409T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800551T1 (cg-RX-API-DMAC7.html)
UA (1) UA121857C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015131031A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606610B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069420A (ko) * 2016-12-15 2018-06-25 가톨릭대학교 산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PE20120371A1 (es) 2009-05-22 2012-05-17 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
DK3354652T3 (da) 2010-03-10 2020-05-18 Incyte Holdings Corp Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
UA121098C2 (uk) 2013-01-15 2020-04-10 Інсайт Холдинґс Корпорейшн Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
SMT201900081T1 (it) 2013-03-06 2019-05-10 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
PE20200527A1 (es) 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak
HRP20200955T1 (hr) 2013-08-07 2020-10-02 Incyte Corporation Dozni oblici s produženim oslobađanjem za jak1 inhibitor
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
PE20170300A1 (es) 2014-04-30 2017-04-19 Incyte Corp Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN109072190A (zh) * 2016-03-09 2018-12-21 蔚山大学校产学协力团 将jak1抑制剂作为有效成分包含的用于干细胞的增殖、分化促进或老化抑制的组成物
KR102485731B1 (ko) 2017-01-23 2023-01-05 상하이 롱우드 바이오파마슈티칼스 컴퍼니 리미티드 Jak 효소 억제제 및 이의 제조 방법과 용도
CN109867676B (zh) * 2017-12-01 2020-10-30 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
IL276302B2 (en) 2018-01-30 2023-11-01 Incyte Corp Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
EP3746149B1 (en) 2018-02-01 2025-08-06 Shifamed Holdings, LLC Intravascular blood pumps
KR20240157777A (ko) 2018-02-16 2024-11-01 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
EA202191170A1 (ru) * 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
IL285999B1 (en) * 2019-03-05 2025-09-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
AU2020356575A1 (en) 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN111358791A (zh) * 2020-03-13 2020-07-03 深圳百奥捷生物科技有限公司 Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用
BR112022024632A2 (pt) 2020-06-02 2023-02-28 Incyte Corp Processos para preparar um inibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
US20240091215A1 (en) * 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CA3219092A1 (en) 2021-05-03 2022-11-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2024222835A1 (en) * 2023-04-27 2024-10-31 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2002215608B2 (en) 2000-06-28 2004-12-09 Smithkline Beecham P.L.C. Wet milling process
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
CN1582150B (zh) 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
UA116187C2 (uk) * 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
NZ587928A (en) 2008-03-11 2012-08-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK3354652T3 (da) * 2010-03-10 2020-05-18 Incyte Holdings Corp Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PH12013501001A1 (en) * 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US20140073643A1 (en) * 2010-12-03 2014-03-13 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
AR086983A1 (es) * 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) * 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US10155987B2 (en) * 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
AR093308A1 (es) * 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
PE20200527A1 (es) * 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069420A (ko) * 2016-12-15 2018-06-25 가톨릭대학교 산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물

Also Published As

Publication number Publication date
BR112016019511A8 (pt) 2023-01-24
CA2940659A1 (en) 2015-09-03
CA2940659C (en) 2023-01-03
US20220378791A1 (en) 2022-12-01
NZ724464A (en) 2021-01-29
MY185392A (en) 2021-05-17
EA201691745A1 (ru) 2016-12-30
AU2015222913B2 (en) 2019-12-12
CY1120857T1 (el) 2019-12-11
SMT201800551T1 (it) 2019-01-11
DK3110409T3 (en) 2018-10-22
MX372939B (es) 2020-04-03
IL247475B (en) 2020-05-31
PL3110409T3 (pl) 2018-12-31
IL247475A0 (en) 2016-11-30
CR20160449A (es) 2016-12-20
AU2015222913A1 (en) 2016-09-29
WO2015131031A1 (en) 2015-09-03
CN112494652A (zh) 2021-03-16
JP6576941B2 (ja) 2019-09-18
EP3110409B1 (en) 2018-08-15
UA121857C2 (uk) 2020-08-10
CN106456773A (zh) 2017-02-22
SG11201607083VA (en) 2016-09-29
HUE041456T2 (hu) 2019-05-28
US20190111058A1 (en) 2019-04-18
SG10201807952PA (en) 2018-10-30
PT3110409T (pt) 2018-11-07
ZA201606610B (en) 2020-08-26
LT3110409T (lt) 2019-01-25
SI3110409T1 (sl) 2018-11-30
PE20161388A1 (es) 2016-12-28
ES2688553T3 (es) 2018-11-05
CL2016002144A1 (es) 2016-12-16
US20210069193A1 (en) 2021-03-11
MX2016011103A (es) 2017-02-28
US20150246046A1 (en) 2015-09-03
JP2017506659A (ja) 2017-03-09
HRP20181661T1 (hr) 2018-12-14
BR112016019511A2 (cg-RX-API-DMAC7.html) 2017-08-15
RS57723B1 (sr) 2018-12-31
EP3110409A1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
EP3110409B1 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
EP2721028B1 (en) Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9193733B2 (en) Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
DK3050882T3 (en) PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
CA2921568A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
CA2818542A1 (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2007340530A1 (en) Novel aminopyrimidine derivative as PLK1 inhibitor
EP3596064A1 (en) Tosylacetate based compounds and derivatives thereof as phgdh inhibitors
EP3691642B1 (en) [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors
HK1231762A1 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
HK1231762B (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
EA040337B1 (ru) Ингибиторы jak1 для лечения миелодиспластических синдромов
NZ724464B2 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
BR112016019511B1 (pt) Uso de inibidores de jak1 para o tratamento de síndromes mielodisplásicas
HK40077703A (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK40077703B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK1258929B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK1197056B (en) Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210903

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220225

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220225

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20210903

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220701

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20211103

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221017

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220930

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220701

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20220225

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20211103

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210903

X601 Decision of rejection after re-examination